Healthcare provider profile · identity verified

David William Kopp, MD

Internal Medicine · FAIRPORT, NY · NPI 1134198849

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	598	202
Losartan Potassium	Losartan Potassium	445	143
Levothyroxine Sodium	Levothyroxine Sodium	363	100
Amlodipine Besylate	Amlodipine Besylate	354	107
Lisinopril	Lisinopril	352	106
Metoprolol Succinate	Metoprolol Succinate	351	110
Omeprazole	Omeprazole	253	79
Pantoprazole Sodium	Pantoprazole Sodium	191	52
Hydrochlorothiazide	Hydrochlorothiazide	189	58
Gabapentin	Gabapentin	181	53
Rosuvastatin Calcium	Rosuvastatin Calcium	174	53
Eliquis	Apixaban	171	40
Escitalopram Oxalate	Escitalopram Oxalate	157	54
Tamsulosin Hcl	Tamsulosin Hcl	144	48
Metformin Hcl Er	Metformin Hcl	140	50
Trazodone Hcl	Trazodone Hcl	128	35
Torsemide	Torsemide	123	48
Meloxicam	Meloxicam	121	41
Allopurinol	Allopurinol	116	37
Chlorthalidone	Chlorthalidone	107	36
Duloxetine Hcl	Duloxetine Hcl	105	30
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	104	33
Prednisone	Prednisone	104	73
Glipizide Er	Glipizide	96	28
Metformin Hcl	Metformin Hcl	93	32
Fluticasone Propionate	Fluticasone Propionate	92	33
Simvastatin	Simvastatin	92	29
Famotidine	Famotidine	90	27
Alprazolam	Alprazolam	85	30
Jardiance	Empagliflozin	84	21
Clonazepam	Clonazepam	76	17
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	76	24
Mirtazapine	Mirtazapine	76	22
Sertraline Hcl	Sertraline Hcl	76	21
Atenolol	Atenolol	74	27
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	73	21
Pravastatin Sodium	Pravastatin Sodium	73	24
Zolpidem Tartrate	Zolpidem Tartrate	68	13
Alendronate Sodium	Alendronate Sodium	66	17
Montelukast Sodium	Montelukast Sodium	66	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	64	20
Ozempic	Semaglutide	60	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	55	27
Bupropion Xl	Bupropion Hcl	47	15
Irbesartan	Irbesartan	47	15
Amoxicillin	Amoxicillin	46	29
Doxycycline Hyclate	Doxycycline Hyclate	46	39
Celecoxib	Celecoxib	45	12
Trulicity	Dulaglutide	45	suppressed
Carvedilol	Carvedilol	42	13
Metoprolol Tartrate	Metoprolol Tartrate	42	13
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	42	suppressed
Potassium Chloride	Potassium Chloride	40	13
Lactulose	Lactulose	39	suppressed
Eszopiclone	Eszopiclone	37	suppressed
Finasteride	Finasteride	36	11
Furosemide	Furosemide	35	12
Venlafaxine Hcl Er	Venlafaxine Hcl	35	11
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	34	32
Xarelto	Rivaroxaban	32	suppressed
Baclofen	Baclofen	31	suppressed
Clopidogrel	Clopidogrel Bisulfate	31	11
Synthroid	Levothyroxine Sodium	30	suppressed
Donepezil Hcl	Donepezil Hcl	29	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Pregabalin	Pregabalin	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	17
Spironolactone	Spironolactone	26	suppressed
Tramadol Hcl	Tramadol Hcl	26	11
Oxycodone Hcl	Oxycodone Hcl	23	suppressed
Clobetasol Propionate	Clobetasol Propionate	22	17
Combivent Respimat	Ipratropium/Albuterol Sulfate	22	suppressed
Lorazepam	Lorazepam	22	suppressed
Valsartan	Valsartan	22	suppressed
Haloperidol	Haloperidol	21	suppressed
Citalopram Hbr	Citalopram Hydrobromide	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Labetalol Hcl	Labetalol Hcl	19	suppressed
Propranolol Hcl Er	Propranolol Hcl	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	13
Doxazosin Mesylate	Doxazosin Mesylate	18	suppressed
Valacyclovir	Valacyclovir Hcl	18	suppressed
Azithromycin	Azithromycin	17	16
Insulin Syringe	Syringe And Needle,insulin,1ml	17	suppressed
Diazepam	Diazepam	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	16	16
Sildenafil Citrate	Sildenafil Citrate	16	suppressed
Diclofenac Sodium	Diclofenac Sodium	15	suppressed
Diltiazem 24hr Er (Xr)	Diltiazem Hcl	15	suppressed
Linzess	Linaclotide	15	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	15	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	14	suppressed
Morphine Sulfate Er	Morphine Sulfate	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Ropinirole Hcl	Ropinirole Hcl	14	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Nitroglycerin	Nitroglycerin	13	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Morphine Sulfate	Morphine Sulfate	12	suppressed
Risperidone	Risperidone	12	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	12	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	11	suppressed
Ketoconazole	Ketoconazole	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Oxazepam	Oxazepam	11	suppressed
Primidone	Primidone	11	suppressed
Ramipril	Ramipril	11	suppressed
Spiriva Respimat	Tiotropium Bromide	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed
Warfarin Sodium	Warfarin Sodium	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error